Tags

Type your tag names separated by a space and hit enter

CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases.
Diabetes Res Clin Pract. 2008 Aug; 81(2):258-62.DR

Abstract

In patients with chronic liver diseases (CLD), turnover of erythrocytes is increased whereas that of serum albumin is decreased. Thus, glycated hemoglobin (HbA(1C)) and glycated albumin (GA) cannot be used as adequate indicators for chronic plasma glucose control in diabetic patients with CLD. In this investigation, we have proposed CLD-HbA(1C), a novel long-term glycemic control marker by using measured HbA(1C) and GA. We studied 82 patients with CLD in whom glycemic control was regarded as to be stable. Daily plasma glucose profiles were monitored and estimated levels of HbA(1C) were calculated on the conversion formula established by Rohlfing et al. [C.L. Rohlfing, J.D. England, H.M. Wiedmeyer, A. Tennill, R.R. Little, D.E. Goldstein, Defining the relationship between plasma glucose and HbA1c, Diabetes Care 25 (2002) 275-278]. Cholinesterase (ChE) as an indicator for hepatic function was determined at the same time when HbA(1C) and GA levels were measured. CLD-HbA(1C) was defined as the average of measured HbA(1C) and GA/3, based upon the results that among healthy individuals, GA levels were roughly estimated at approximately threefold higher than HbA(1C) levels. While measured HbA(1C) levels in patients with CLD were generally lower than estimated HbA(1C) levels, GA/3 values were generally higher than estimated HbA(1C) levels. Such discrepancies lineally increased in accordance with a decrease in ChE levels. On the other hand, CLD-HbA(1C) levels were highly correlated with estimated HbA(1C) levels (R=0.883), while no significant correlation between CLD-HbA(1C) and ChE was noted. In conclusion, CLD-HbA(1C) has been found a superior chronic glycemic control marker than HbA(1C) or GA in diabetic patients with chronic liver diseases.

Authors+Show Affiliations

Department of Internal Medicine, Kinki Central Hospital, Kuruma-zuka 3-1, Itami, Hyogo 664-8533, Japan. koga_m@kich.itami.hyogo.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18513821

Citation

Koga, Masafumi, et al. "CLD (chronic Liver diseases)-HbA1C as a Suitable Indicator for Estimation of Mean Plasma Glucose in Patients With Chronic Liver Diseases." Diabetes Research and Clinical Practice, vol. 81, no. 2, 2008, pp. 258-62.
Koga M, Kasayama S, Kanehara H, et al. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract. 2008;81(2):258-62.
Koga, M., Kasayama, S., Kanehara, H., & Bando, Y. (2008). CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Research and Clinical Practice, 81(2), 258-62. https://doi.org/10.1016/j.diabres.2008.04.012
Koga M, et al. CLD (chronic Liver diseases)-HbA1C as a Suitable Indicator for Estimation of Mean Plasma Glucose in Patients With Chronic Liver Diseases. Diabetes Res Clin Pract. 2008;81(2):258-62. PubMed PMID: 18513821.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. AU - Koga,Masafumi, AU - Kasayama,Soji, AU - Kanehara,Hideo, AU - Bando,Yukihiro, Y1 - 2008/06/02/ PY - 2007/07/01/received PY - 2008/04/08/accepted PY - 2008/6/3/pubmed PY - 2008/8/21/medline PY - 2008/6/3/entrez SP - 258 EP - 62 JF - Diabetes research and clinical practice JO - Diabetes Res Clin Pract VL - 81 IS - 2 N2 - In patients with chronic liver diseases (CLD), turnover of erythrocytes is increased whereas that of serum albumin is decreased. Thus, glycated hemoglobin (HbA(1C)) and glycated albumin (GA) cannot be used as adequate indicators for chronic plasma glucose control in diabetic patients with CLD. In this investigation, we have proposed CLD-HbA(1C), a novel long-term glycemic control marker by using measured HbA(1C) and GA. We studied 82 patients with CLD in whom glycemic control was regarded as to be stable. Daily plasma glucose profiles were monitored and estimated levels of HbA(1C) were calculated on the conversion formula established by Rohlfing et al. [C.L. Rohlfing, J.D. England, H.M. Wiedmeyer, A. Tennill, R.R. Little, D.E. Goldstein, Defining the relationship between plasma glucose and HbA1c, Diabetes Care 25 (2002) 275-278]. Cholinesterase (ChE) as an indicator for hepatic function was determined at the same time when HbA(1C) and GA levels were measured. CLD-HbA(1C) was defined as the average of measured HbA(1C) and GA/3, based upon the results that among healthy individuals, GA levels were roughly estimated at approximately threefold higher than HbA(1C) levels. While measured HbA(1C) levels in patients with CLD were generally lower than estimated HbA(1C) levels, GA/3 values were generally higher than estimated HbA(1C) levels. Such discrepancies lineally increased in accordance with a decrease in ChE levels. On the other hand, CLD-HbA(1C) levels were highly correlated with estimated HbA(1C) levels (R=0.883), while no significant correlation between CLD-HbA(1C) and ChE was noted. In conclusion, CLD-HbA(1C) has been found a superior chronic glycemic control marker than HbA(1C) or GA in diabetic patients with chronic liver diseases. SN - 1872-8227 UR - https://www.unboundmedicine.com/medline/citation/18513821/CLD__chronic_liver_diseases__HbA1C_as_a_suitable_indicator_for_estimation_of_mean_plasma_glucose_in_patients_with_chronic_liver_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(08)00194-0 DB - PRIME DP - Unbound Medicine ER -